[CT-guidance interstitial Iodine-125 seed brachytherapy as a salvage therapy for recurrent head and neck carcinoma]

Zhonghua Yi Xue Za Zhi. 2018 Dec 4;98(45):3686-3691. doi: 10.3760/cma.j.issn.0376-2491.2018.45.011.
[Article in Chinese]

Abstract

Objective: To investigate the efficacy of CT-guidance interstitial Iodine-125 seed brachytherapy as a salvage therapy for recurrent head and neck carcinoma. Methods: A total of 122 patients who had been treated for recurrent head and neck carcinoma with CT-guided Iodine-125 seed permanent implantation were conducted a retrospective analysis at Peking University Third Hospital from February 2003 to December 2015. The study included 78 male and 44 female patients. Of the 122 patients, 76 had undergone radical surgery, 106 had received EBRT. Among the patients who underwent EBRT, the total dose delivered to PTV ranged from 30 to 140 Gy (median, 68.4 Gy). The actuarial median number of the implanted Iodine-125 seeds was 38 (range, 5-158). The specific activity of Iodine-125 seeds ranged from 14.8 to 28.9 MBq/seed (median, 22.2 MBq). The evaluation of post plan showed the actuarial D90 ranged from 46 to 282 Gy (median, 121 Gy). The overall local control and survival times were determined by using the Kaplan-Meier method from SPSS 13.0.Univariate analysis was performed on the local control rate and overall survival rate. Results: Tumor responses rate was 75.4%. The median local control time was 10.0 months (95% CI 9.8-24.2 months), and the 1-, 2-, 3-, and 5-year local control were 41.9%, 21.2%, 3.7%, and 3.7%, respectively. Univariate analysis showed that the local control in D90≥120 Gy group had an increasing tendency, but no statistical difference were found. The effect of local control in the squamous cell carcinoma group was slightly worse than that in the non-squamous cell carcinoma group (P=0.032). Multi-factor analysis showed that the effect of local control in the squamous cell carcinoma group was slightly poor (P=0.03). The median survival time was 14 months (95% CI 14.4-35.8 months), and the 1-, 2-, 3- and 5-year survival rate were 51.5%, 34.2%, 19.4%, and 19.4%, respectively. The three factors, such as the tumor responses, KPS status before the seed implantation, and the D90 after the seed implantation, had a tendency to improve the total survival, but there was still no statistical differences. Multivariate analysis showed no clear influence factors. Conclusions: Interstitial permanent Iodine-125 seed implantation is an effective salvage re-irradiation modality for recurrent head and neck carcinoma after previous surgery and/or EBRT. CT image-guided method could yield the reliable seeds configuration and accurate dose distribution.

目的: 探讨CT引导下放射性(125)I粒子植入治疗头颈部复发/转移恶性肿瘤的有效性。 方法: 回顾性分析2003年2月—2015年12月于北京大学第三医院行CT引导下放射性(125)I粒子植入治疗头颈部复发/转移恶性肿瘤的122例患者。其中男78例、女44例。76例( 62.3%)既往有头颈部手术史。106例(86.9%)有局部外放疗史。外放疗总累积剂量为30~140 Gy,中位剂量为68.4 Gy。在CT扫描下参照术前计划植入粒子,粒子数目为5~158枚,中位粒子数38枚。(125)I粒子的活度范围为14.8~28.9 MBq /枚,中位活度为22.2 MBq。术后验证PTV剂量范围D90为46~282 Gy,中位剂量为121 Gy。对肿瘤局部控制率、生存率进行单因素及多因素分析。 结果: 总体客观缓解率为75.4%。中位局部控制时间为10个月(95% CI 9.8~24.2个月)。1、2、3及5年局部控制率分别为41.9%、21.2%、3.7%及3.7%。单因素分析结果显示,粒子植入术后D90≥120 Gy组的局部控制从曲线上看有增加趋势,但差异无统计学意义(P=0.148)。鳞癌的局部控制效果低于非鳞癌(P=0.032)。多因素分析提示鳞癌的局部控制效果差(P=0.03)。全组中位生存时间为14个月(95% CI 14.4~35.8个月)。1、2、3及5年生存率分别为51.5%、34.2%、19.4%及19.4%。单因素分析结果显示,肿瘤客观缓解率、术前KPS>80分、术后D90≥120 Gy三个因素从生存曲线上看对总生存有提高趋势,但差异无统计学意义。所有病例未发生3级以上放射性损伤。 结论: 组织间(125)I粒子植入治疗复发性头颈部癌,是一种有效的挽救治疗手段。经CT引导下的粒子植入,植入粒子位置准确可靠,剂量分布精确。.

Keywords: Head and neck neoplasms; Iodine isotopes; Recurrence; Tomography, X-ray computed.

MeSH terms

  • Brachytherapy*
  • Female
  • Humans
  • Iodine Radioisotopes
  • Male
  • Neoplasm Recurrence, Local
  • Retrospective Studies
  • Salvage Therapy*
  • Tomography, X-Ray Computed

Substances

  • Iodine Radioisotopes